The firm is leveraging its expertise in the immuno-oncology space to expedite development of newer agents like the bispecific ...

Bristol-Myers Squibb Company (BMY) reported second-quarter 2025 adjusted earnings per share (EPS) of $1.46, which comfortably ...

The sector’s expansion is attributed to rising incidence rates. The triple-negative breast cancer (TNBC) market across the ...

The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved diagnostics ...

The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from ...

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

Bristol Myers is making waves after a period of pressure. The stock jumped 6.3% recently, outperforming its industry and the ...

Sotyktu (deucravacitinib) has been assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 6, 2026.

Summit Therapeutics' HARMONi trial data for ivonescimab showed a clinical benefit but narrowly missed statistical significance on overall survival. Learn more on SMMT stock here.

Bristol Myers SquibbBMY announced a strategic collaboration agreement with BioNTechBNTX for the global co-development and ...